No profile data available.
TriSalus Life Sciences, Inc. (TLSI) is a healthcare company in the IV treatment equipment industry, based in Westminster, United States, with about 102 full-time employees.
It reported revenue of $45.15 million for fiscal year 2025, up 53.4% from fiscal year 2024, and net income of -$69.69 million. Its market capitalization was $269.70 million as of October 5, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 5, 2026.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
TriSalus Life Sciences reported $45.15 million in revenue for fiscal year 2025, up 53.4% from $29.43 million in fiscal year 2024.
$269.70 million as of October 5, 2026.
Listed companies of a similar size in the same industry (IV treatment equipment) include Beta Bionics, Inc. (BBNX), CorMedix Inc. (CRMD), Delcath Systems, Inc. (DCTH), Koru Medical Systems, Inc. (KRMD).